Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 29;32(5):513–520. doi: 10.1038/s41431-023-01494-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Cumulative incidence for any cancer by sex, age-group and carriership status. Data for MSH2 mutations carriers from the Prospective Lynch Syndrome Database [14] (smoothed), and data for non-carriers from Cancer Incidence in Five Continents [28], Norway 2008–2012. B Co-segregation sensitivity analysis, showing the contours of the FLB factor as a function of the risk of cancer in non-carriers and the excess rate in carriers. The robustness of the results was evaluated by recomputing the FLB under a range of ever-more conservative penetrance parameters: we varied the cumulative incidences in non-carriers by a factor of 0.50–1.50 and, for each value of this factor, the incidence rates of MSH2 carriers were also varied as a weighted average between the non-carrier incidence rates and their original estimates. These endpoints are represented as 0–100% excess cancer rates, respectively. The cross corresponds to the main co-segregation result reported in the study. The contour curve at FLB = 16 signifies the threshold for pathogenic strong evidence according to Jarvik and Browning [31].